Market cap
$641 Mln
Revenue (TTM)
$117 Mln
P/E Ratio
--
P/B Ratio
8.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 74.27 | 118.37 | 292.05 | 150.27 | 108.23 |
| EBIT | 39.67 | 24.30 | 6.66 | -28.54 | -9.44 |
| Net Profit | 45.37 | 18.38 | -22.94 | -42.08 | -38.21 |
| EPS | 45.38 | 18.38 | -22.93 | 3.72 | 9.33 |
| Book Value | -- | -- | -58.32 | -35.96 | -27.59 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -197.90 | -344.20 | -2,379.34 |
| Net Margin
| -- | -- | -238.62 | -- | -- |
| Return on equity
| -- | -- | -221.39 | -95.20 | -81.91 |
| Return on Capital
| -- | -- | -- | -57.09 | -68.49 |
| Return on Assets
| -- | -- | -34.60 | -42.02 | -38.11 |
| Debt to Equity (x)
| -- | -- | 0.00 | 1.97 | 0.12 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
-57.09
|
-68.49
|
-126.72
|
-85.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-221.39
Lower than Peers by 181.10
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-221.39
|
-95.20
|
-81.91
|
-186.93
|
-101.61
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-34.60
Lower than Peers by 3.77
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-34.60
|
-42.02
|
-38.11
|
-55.51
|
-48.14
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
-197.90
Lower than Peers by 115.69
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-197.90
|
-344.20
|
-2,379.34
|
-9,619.26
|
-11,485.75
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
-238.62
Lower than Peers by 148.73
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-238.62
|
-381.40
|
-2,180.45
|
-12,272.26
|
-12,272.26
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
292.05
Higher than Peers by 238.01
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
292.05
|
6.47
|
4.96
|
-0.73
|
-0.73
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
6.66
Higher than Peers by 7.62
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
6.66
|
-8.02
|
-47.42
|
-16.95
|
-19.08
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
-22.94
Lower than Peers by 15.75
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-22.94
|
-30.61
|
-5.89
|
-40.01
|
-40.01
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
-22.93
Lower than Peers by 37.36
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-22.93
|
-0.31
|
0.31
|
0.06
|
0.27
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
-78.40
Lower than Peers by 67.94
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-78.40
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
1.97
|
0.12
|
0.48
|
0.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.08
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
0.08
|
0.08
|
0.01
|
0.05
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.89
Lower than Peers by 0.92
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
4.89
|
5.94
|
10.88
|
6.15
|
6.15
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
4.40
Lower than Peers by 1.29
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
4.40
|
5.48
|
10.81
|
6.68
|
6.70
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-4.93
Lower than Peers by 2.84
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
-4.93
|
-7.08
|
-25.91
|
-3.62
|
-4.33
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
37.83
Higher than Peers by 18.85
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
37.83
|
100.30
|
476.68
|
61.66
|
1,445.35
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
0.15
Higher than Peers by 0.08
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
0.15
|
0.11
|
0.02
|
0.00
|
0.00
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
299.76
|
889.43
|
2,752.17
|
5,756.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
70.61
|
-25.07
|
-1,336.29
|
-288.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
9.55
|
2.68
|
5.73
|
17.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
360.81
|
861.68
|
1,410.15
|
5,449.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
-1.84
|
-2.83
|
-5.38
|
-1.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
8.55
Higher than Peers by 3.20
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
8.55
|
2.97
|
1.46
|
10.05
|
3.64
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.03
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
0.03
|
-2.32
|
-0.39
|
-5.96
|
-1.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
641
Higher than Peers by 494
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Sep-23
|
|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
641
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|